Processes for the preparation of substituted spirooxindole derivatives

Inventors

Zhu, Kaicheng • Wang, Tao • Zhang, Xin • Peng, Xiaowen • Shen, Ruichao • Zhang, Jiajun • Li, Wei • Cao, Hui • Gao, Xuri • Wang, Guoqiang • Wu, George G. • Or, Yat Sun

Assignees

Enanta Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12747248-B2

Patent

Publication Date

2026-09-29

Expiration Date


Abstract

The present invention relates to processes for preparing a compound of Formula (A): or a pharmaceutically acceptable salt or solvate thereof. Compound of Formula (A) and pharmaceutical compositions are useful as SARS-CoV-2 3CL pro inhibitors.

Core Innovation

The disclosure describes processes for producing substituted spirooxindole compounds of Formula (A), identified as SARS-CoV-2 3CLpro inhibitors, through interconnected intermediate pathways. An intermediate sequence derived from Formula (W) proceeds through intermediates to spirooxindole amine Formula (M), while a second sequence prepares indole carboxylic acid Formula (J) via Hemetsberger indole cyclization. These intermediates combine to provide Formula (N), followed by conversion to Formula (A), with defined substituent, protecting-group, and anion choices.

The disclosure further describes an alternative sequence for preparing Formula (J) involving formation and regeneration of a bisulfite adduct, as well as diastereomer-enriched intermediates. Isolation of Formula (A) occurs as a toluene solvate or amorphous solid characterized by PXRD and DSC. Detailed synthetic operations are [procedural detail omitted for safety], while the processes emphasize improved yield, safety, and scalability for large-scale production.

Claims Coverage

The patent claims identify four inventive features across independent claims 1, 5, 9, and 12, covering related multistep processes for producing Formula (A) through interconnected intermediate pathways.

Production of Formula (A) with preparation of Formula (J)

Independent claim 1 covers a process for producing Formula (A) through intermediates including Formulas (B), (C), (D-1), (e-1), (F-1), (L), (M), (N), and (J), wherein Formula (J) is prepared through reduction, oxidation, and Hemetsberger indole cyclization of compounds (G-a), (G-b), (G), (H), and (I) [procedural detail omitted for safety].

Production of Formula (A) using Formula (J)

Independent claim 5 covers a process for producing Formula (A) through a sequence proceeding from Formula (W) through Formula (B), Formula (C), Formula (D-1), compound (e-1), Formula (F-1), Formula (L), and Formula (M) or a salt thereof, followed by reaction with Formula (J) to provide Formula (N) and conversion to Formula (A), defining choices for substituents, anions, and protecting groups [procedural detail omitted for safety].

Preparation of Formula (A) with defined intermediate options

Independent claim 9 covers a process for preparing Formula (A) through the intermediate sequence from Formula (B) to Formula (M), followed by reaction with Formula (J) to provide Formula (N) and conversion to Formula (A), specifying defined choices for R¹, R², G¹, X, and PG¹ [procedural detail omitted for safety].

Production of Formula (A) including a bisulfite-adduct route

Independent claim 12 covers a process for producing Formula (A) that includes preparing Formula (J) through compounds (G-a), (G-b), (G), (G-c), (H), and (I) via Hemetsberger indole cyclization and an alternative capture-and-release sequence forming a bisulfite adduct from Formula (G) and converting it back to Formula (G), followed by combining intermediates to provide Formula (N) and conversion to Formula (A) [procedural detail omitted for safety].

The four inventive features cover related multistep processes for producing Formula (A) through intermediate pathways, distinguishing intermediate sequences leading to Formula (J), variable substituent selections, and the inclusion of a bisulfite-adduct pathway.

Stated Advantages

The disclosure emphasizes improved yield, safety, and scalability for large-scale production.

Documented Applications

Production of substituted spirooxindole compounds of Formula (A), identified in the disclosure as SARS-CoV-2 3CLpro inhibitors.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.